📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
Indoco Remedies receives EIR from USFDA for Patalganga API facility
Indoco Remedies announced it received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility at Patalganga, following an inspection from September 15-19, 2025. This signifies successful completion of the USFDA inspection. The company's turnover is US$ 180 million. This approval reinforces Indoco's commitment to quality and compliance.
Key Highlights
Received EIR from USFDA for API facility at Patalganga
Inspection conducted from September 15th to 19th, 2025
Company turnover is US$ 180 million
Employs over 6000 employees
👀 What to Watch
This USFDA approval is a positive sign for Indoco Remedies. Investors should monitor the company's ability to leverage this approval to expand its presence in the US market.
Indoco Remedies Promoters Transfer 51.27% Stake via Inter-se Family Arrangement
Promoters of Indoco Remedies have completed a significant inter-se transfer of shares involving a 51.27% total stake (direct and indirect) to the Kare Family Private Trust (KFPT) and Aruna Suresh Kare. The transaction, executed on November 25, 2025, was a gift-based transfer for succession planning and did not involve any cash consideration. Specifically, 14.20% was transferred directly, while 37.07% was transferred indirectly through holding companies Shanteri Investment Private Limited and SPA Holdings Private Limited. This consolidation streamlines the family's control under a trust structure without changing the overall promoter group holding.
Key Highlights
Kare Family Private Trust (KFPT) and Aruna Suresh Kare acquired 1,30,97,055 equity shares (14.20%) through direct inter-se transfers.
KFPT indirectly acquired 37.07% voting rights by taking controlling stakes in promoter entities SIPL (17.19%) and SHPL (19.88%).
The total direct and indirect acquisition amounts to 51.27% of the company's share capital (51.13% on a diluted basis).
The transfers were executed at nil consideration as gifts for the purpose of smooth succession planning and streamlining family assets.
Post-transaction, KFPT holds an 8.20% direct stake and 37.07% indirect stake, while Aruna Suresh Kare's direct stake stands at 6.00%.
👀 What to Watch
This is an internal promoter restructuring for succession planning and does not impact the company's business fundamentals or overall promoter group control. Investors should treat this as a neutral administrative event.
